SEC Form 8-K Summary
Registrant: MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc. The filing reports events occurring April 29, 2021 and was signed May 3, 2021. MedTech was a Nasdaq-listed special purpose acquisition company with units, Class A common stock, and warrants.
Business Context and Reporting Period
This is a corporate governance filing under Item 5.02. It does not report operating results or a quarterly or annual financial period.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, valuation, or other financial performance metrics.
Material Changes
- On April 29, 2021, the board appointed Manuel “Manny” Aguero and David L. Treadwell as directors.
- The board cited Mr. Aguero’s healthcare and medical technology experience and Mr. Treadwell’s public-company board and executive experience as qualifications.
- The company entered into letter agreements and indemnification agreements with both directors, substantially similar to those signed by the other directors in connection with the company’s initial public offering.
- The filing states that no transactions with either director required disclosure under Item 404(a) of Regulation S-K.
Outlook, Risks, and Unusual Items
No guidance, operating outlook, contingencies, material risks, or unusual financial items are disclosed. The principal reported development is the addition of two directors and related contractual arrangements.
Investor Verification Items
- Verify the correct issuer: the filing identifies MedTech Acquisition Corporation rather than Trisalus Life Sciences, Inc.
- Review the director letter and indemnification agreements for compensation, obligations, and other terms.
- Confirm the board’s composition and any subsequent changes after April 29, 2021.
- Because this filing contains no financial statements, consult the company’s other SEC filings for trust assets, liquidity, transaction status, and financial condition.